OverviewSuggest Edit
AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs. The company offers Humira, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; Imbruvica, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and Viekira Pak, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C.
| Type | Public | |
| Founded | 2013 | |
| HQ | Lake Bluff, US | Map |
| Website | abbvie.com | |
| Employee Ratings | More |
Key People/Management at AbbVie
Richard Gonzalez
Chairman of the Board and Chief Executive Officer
Carlos Alban
Vice Chairman, Chief Commercial Officer
Timothy Richmond
Chief Human Resources Officer, EVP
Azita Saleki-Gerhardt
Executive Vice President, Operations
Laura Schumacher
Executive Vice President, External Affairs, General Counsel and Corporate Secretary
William Chase
Executive Vice President, Finance and Administration
AbbVie Office Locations
AbbVie has offices in Lake Bluff, Sunnyvale, South San Francisco, Cambridge and in 51 other locations
Lake Bluff, US (HQ)
1 Waukegan Rd
Cambridge, US
200 Sidney St
Mettawa, US
26525 Riverwoods Blvd
North Chicago, US
1401 Sheridan Rd
Redwood City, US
1500 Seaport Blvd
South San Francisco, US
450 E Jamie Ct
AbbVie Financials and Metrics
AbbVie Revenue
AbbVie's revenue was reported to be $25.64 b in FY, 2016 which is a 12.2% increase from the previous period.
| USD | |
|---|---|
Revenue (Q2, 2019) | 8.3b |
Gross profit (Q2, 2019) | 6.4b |
Gross profit margin (Q2, 2019), % | 78% |
Net income (Q2, 2019) | 741.0m |
EBIT (Q2, 2019) | 3.4b |
Market capitalization (10-Jun-2019) | 113.8b |
Closing stock price (10-Jun-2019) | 77.0 |
Cash (30-Jun-2019) | 5.2b |
EV | 108.9b |
AbbVie's current market capitalization is $113.8 b.
- Source: SEC Filings
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 18.8b | 20.0b | 22.9b | 25.6b |
Revenue growth, % | 6% | 15% | 12% | |
Cost of goods sold | 4.6b | 4.4b | 4.5b | 5.8b |
Gross profit | 14.2b | 15.5b | 18.4b | 19.8b |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 4.7b | 4.6b | 4.9b | 5.0b | 5.0b | 5.5b | 5.9b | 6.0b | 6.5b | 6.4b | 6.5b | 6.9b | 7.0b | 7.9b | 8.3b | 8.2b | 7.8b | 8.3b |
Cost of goods sold | 1.1b | 1.1b | 1.1b | 1.1b | 942.0m | 916.0m | 1.2b | 1.4b | 1.4b | 1.5b | 1.6b | 1.5b | 1.6b | 1.9b | 1.9b | 1.8b | 1.7b | 1.8b |
Gross profit | 3.6b | 3.5b | 3.8b | 3.9b | 4.1b | 4.6b | 4.8b | 4.6b | 5.0b | 4.9b | 4.9b | 5.4b | 5.4b | 6.0b | 6.3b | 6.4b | 6.1b | 6.4b |
Gross profit Margin, % | 77% | 76% | 77% | 78% | 81% | 83% | 80% | 77% | 78% | 77% | 75% | 78% | 77% | 76% | 77% | 78% | 78% | 78% |
- Source: SEC Filings
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 9.6b | 8.3b | 8.4b | 5.1b |
Accounts Receivable | 3.9b | 3.7b | 4.7b | 4.8b |
Inventories | 1.2b | 1.1b | 1.7b | 1.4b |
Current Assets | 17.8b | 16.1b | 16.3b | 16.2b |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 9.0b | 8.1b | 9.1b | 7.7b | 7.9b | 7.4b | 9.2b | 7.6b | 6.3b | 6.2b | 4.7b | 6.1b | 8.4b | 9.0b | 3.5b | 8.0b | 4.9b | 5.2b |
Accounts Receivable | 3.8b | 3.7b | 3.7b | 3.6b | 4.2b | 4.4b | 4.6b | 4.8b | 5.0b | 5.0b | 4.7b | 4.9b | 4.9b | 5.8b | 5.8b | 5.8b | 5.7b | 5.5b |
Inventories | 1.2b | 1.1b | 1.0b | 1.0b | 1.0b | 1.6b | 1.8b | 1.8b | 1.8b | 1.6b | 1.4b | 1.6b | 1.8b | 1.7b | 1.6b | 1.8b | 1.7b | 1.9b |
Current Assets | 16.5b | 17.3b | 17.8b | 17.6b | 15.4b | 16.9b | 17.9b | 16.6b | 16.8b | 16.3b | 15.5b | 17.0b | 18.9b | 20.4b | 13.8b | 18.5b | 14.4b | 15.1b |
- Source: SEC Filings
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 4.1b | 1.8b | 5.1b | 6.0b |
Inventories | (56.0m) | (203.0m) | (434.0m) | (38.0m) |
Accounts Payable | (426.0m) | (193.0m) | 1.5b | (1.2b) |
Cash From Operating Activities | 6.3b | 3.5b | 7.5b | 7.0b |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 3.0b | 980.0m | 2.1b | 2.6b | 1.0b | 2.4b | 3.6b | 1.4b | 3.0b | 4.6b | 1.7b | 3.6b | 5.3b | 2.8b | 4.8b | 7.5b | 2.5b | 3.2b |
Depreciation and Amortization | 697.0m | 199.0m | 401.0m | 593.0m | 158.0m | 348.0m | 575.0m | 268.0m | 557.0m | 861.0m | 374.0m | 753.0m | 1.1b | 445.0m | 888.0m | 1.3b | 503.0m | 1.0b |
Inventories | (86.0m) | 50.0m | 97.0m | 20.0m | (75.0m) | (160.0m) | (446.0m) | 19.0m | (160.0m) | 28.0m | 71.0m | 1.0m | (119.0m) | (71.0m) | (191.0m) | (367.0m) | (128.0m) | (288.0m) |
Accounts Payable | 227.0m | (612.0m) | (217.0m) | (1.0m) | 188.0m | 409.0m | 1.3b | 42.0m | 89.0m | (975.0m) | (266.0m) | (530.0m) | 444.0m | 191.0m | 12.0m | 881.0m | 94.0m | (1.3b) |
- Source: SEC Filings
| USD | Y, 2019 |
|---|---|
EV/EBIT | 29.3 x |
Financial Leverage | -6.7 x |
AbbVie Acquisitions / Subsidiaries
| Acquired Company | Date | Deal Size |
|---|---|---|
| Allergan | June 25, 2019 | $80 b |
| Stem CentRx | April 28, 2016 | $5.80 b |
AbbVie Online and Social Media Presence
53.83k Twitter followers
AbbVie has 53.83k Twitter Followers. The number of followers has increased 1.3% month over month and increased 5% quarter over quarter
AbbVie's Trends
Twitter Engagement Stats for @abbvie
5.8k
Tweets
492
Following
53.8k
Followers
54
Tweets last 30 days
5.9
Avg. likes per Tweet
85.2%
Tweets with engagement
AbbVie News and Updates
September 12, 2019
Consumer groups, unions urge caution on $63 bln AbbVie deal for Allergan
About a dozen advocacy
groups and unions, including Public Citizen and the American
Federation of Teachers, wrote the Federal Trade Commission on
Thursday urging it to consider blocking drugmaker AbbVie Inc's
planned $63 billion purchase of Botox maker Allergan
Plc.
August 29, 2019
AbbVie is shutting down its troubled Rova-T R&D program
Shares of AbbVie Inc. rose 1.5% in premarket trade Thursday after the company announced it had shut down its troubled Rova-T research and development program. The drugmaker said it was discontinuing a late-stage trial of Rova-T as a potential treatment for advanced small-cell lung cancer after inte…
August 29, 2019
AbbVie terminates late-stage lung cancer trial
AbbVie Inc on Thursday said it
will discontinue the late-stage trial testing its experimental
treatment for a type of lung cancer after it failed to show a
survival benefit compared to placebo.
August 29, 2019
AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program
NORTH CHICAGO, Ill., Aug. 29, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research based global biopharmaceutical company, today announced that MERU, a Phase 3 trial evaluating Rova-T as a first-line maintenance therapy for advanced small-cell lung cancer (SCLC), demonstrated no survival...
August 20, 2019
Here are the biggest analyst calls of the day: Beyond Meat, AbbVie, Hewlett Packard & more
Here are the biggest calls on Wall Street on Tuesday.
AbbVie Frequently Asked Questions
When was AbbVie founded?
AbbVie was founded in 2013.
Who are AbbVie key executives?
AbbVie's key executives are Richard Gonzalez, Carlos Alban and Timothy Richmond.
How many employees does AbbVie have?
AbbVie has 30,000 employees.
What is AbbVie revenue?
Latest AbbVie annual revenue is $25.6 b.
What is AbbVie revenue per employee?
Latest AbbVie revenue per employee is $854.6 k.
Who are AbbVie competitors?
Competitors of AbbVie include Bristol-Myers Squibb, Abbott and Merck.
Where is AbbVie headquarters?
AbbVie headquarters is located at 1 Waukegan Rd, Lake Bluff.
Where are AbbVie offices?
AbbVie has offices in Lake Bluff, Sunnyvale, South San Francisco, Cambridge and in 51 other locations.
How many offices does AbbVie have?
AbbVie has 60 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies